| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Realized loss on marketable debt securities | NaN | 0 | 0 | 0 |
| Amortization of debt discount | NaN | 3,423 | 964 | 849 |
| Loss from lease termination | NaN | 0 | 0 | -1,357 |
| Employee retention tax credit income | NaN | 0 | 380 | 1,549 |
| Accounts receivable allowances | NaN | 1,005 | NaN | NaN |
| Impairment loss | NaN | 0 | 1,263 | NaN |
| Net cash provided by operating activities - discontinued operations | 0 | 0 | 0 | 597 |
| Inventory valuation reserve | NaN | 0 | 0 | 0 |
| Amortization on operating lease right-of-use assets | 0 | 0 | 17 | 210 |
| Inventory write-offs | NaN | 196 | NaN | NaN |
| Deferred tax liability | NaN | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | -313 |
| Change in fair value of warrant liability | NaN | 0 | 185 | 40 |
| Accrued diagnostic services | 0 | 0 | -49 | 44 |
| Depreciation and amortization | 962 | 963 | 1,038 | 2,831 |
| Amortization of debt discount | 476 | NaN | NaN | NaN |
| Loss from investment in unconsolidated affiliates | -225 | -166 | NaN | NaN |
| Loss on issuance of debt | -12 | 0 | -480 | NaN |
| Loss (gain) from disposal of fixed assets | 6 | -87 | 0 | -868 |
| Stock-based compensation expense | 390 | 433 | 431 | 1,029 |
| Change in fair value of derivative liability | -86 | 1,055 | -618 | NaN |
| Debt extinguishment loss | -278 | 1,336 | 220 | -718 |
| Accounts receivable | 7 | -743 | -21 | 28 |
| Prepaid expenses and other current assets | 104 | -2,356 | 406 | 803 |
| Deferred tax asset | NaN | 0 | 0 | 0 |
| Other assets | NaN | 0 | 0 | 0 |
| Accrued advertising and other allowances | NaN | -101 | 0 | 0 |
| Accounts payable and accrued expenses | 1,180 | -1,287 | 117 | 448 |
| Deferred revenue | 484 | 181 | -109 | -410 |
| Lease liabilities | 39 | -82 | -122 | -29 |
| Income tax payable | 512 | -10 | -1,083 | -613 |
| Other liabilities | 79 | 486 | 588 | -350 |
| Loss from continuing operations after income taxes | -5,354 | -7,398 | -6,839 | -9,150 |
| Net cash used in operating activities - continuing operations | -748 | -1,230 | -3,486 | -4,225 |
| Net cash used in operating activities | -748 | -1,230 | -3,486 | -3,628 |
| Proceeds from sales of marketable securities | NaN | NaN | 0 | 0 |
| Net cash provided by investing activities - discontinued operations | 0 | 0 | 0 | 800 |
| Proceeds from maturities of marketable securities | NaN | 0 | NaN | NaN |
| Capital expenditures | 0 | 0 | 0 | 0 |
| Proceeds from sale of fixed assets | 12 | 0 | 0 | 120 |
| Net cash provided by investing activities - continuing operations | 12 | 0 | 0 | 120 |
| Net cash provided by investing activities | 12 | 0 | 0 | 920 |
| Net cash used in financing activities - discontinued operations | 0 | 0 | 0 | -35 |
| Proceeds from issuance of note payable to related party | NaN | 0 | 0 | 500 |
| Proceeds from issuance of common stock from public offering, net | NaN | 0 | NaN | NaN |
| Proceeds from issuance of common shares, net | 41 | 0 | 0 | 3,558 |
| Proceeds from issuance of note payable, net | 288 | 1,160 | 2,227 | 687 |
| Proceeds from issuance of convertible notes payable | 392 | 0 | 3,000 | NaN |
| Repayment of note payable | 44 | 218 | 1,505 | 2,511 |
| Repayment of convertible notes payable | NaN | 27 | NaN | NaN |
| Net cash provided by financing activities - continuing operations | 677 | 915 | 3,722 | 2,234 |
| Net cash provided by financing activities | 677 | 915 | 3,722 | 2,199 |
| Decrease in cash and cash equivalents | -59 | -315 | 236 | -509 |
| Cash and cash equivalents at the beginning of the period | 90 | 405 | 678 | NaN |
| Cash and cash equivalents at the end of the period | 31 | 90 | 405 | NaN |
ProPhase Labs, Inc. (PRPH)
ProPhase Labs, Inc. (PRPH)